We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Ral5.3

Raloxifene (Evista) Research

Mostly mechanism / observational

367 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Raloxifene (Evista) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1999–2025 with a typical study size of 7,705 participants.

Based on 366 studies · 17 meta-analyses · 340 RCTs · 15,448 total participants

Confidence

High confidence

By outcome

Breast cancer & postmenopausal
Mostly mechanism / observational236 studies
Bone health & osteoporosisIn MORE, reduced the risk of new vertebral fractures and increased bone mineral density in postmenopausal women with osteoporosis · Months to years
Mostly mechanism / observational85 studies
Cardiovascular & thrombosis
Mostly mechanism / observational12 studies
Safety profile
Mostly mechanism / observational7 studies

Slowing down

Only 14 studies in the last 5 years · Latest meta-analysis: 2025

199920122025

1Meta-Analysis2020

Davis S, Simpson E, Hamilton J, James MM, Rawdin A, Wong R · Health Technol Assess (2020)

Raloxifene (Evista) Research

Mostly mechanism / observational

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

The effect of raloxifene supplementation on blood pressure and Apo-lipoproteins in postmenopausal women: A systematic review and meta-analysis.

Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.

Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.

Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.

Effect of Raloxifene Treatment on Apolipoproteins and Lipoprotein(a) Concentrations in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials.

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.

Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.

The effects of raloxifene on endothelial function and Inflammation in Postmenopausal women: A Meta-analysis of randomized controlled trials.

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials.

Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.

Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials.

The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Raloxifene as an Adjuvant Therapy for Patients With Schizophrenia: An Up-To-Date Systematic Review and Meta-Analysis.

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Selective oestrogen receptor modulators (SERMs) for endometriosis.